Author’s response to reviews

Title: Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study. MetAbolism vaRiability of VEnLafaxine (MARVEL study)

Authors:

Célia Lloret-Linares (celialloret@yahoo.fr)
Youssef Daali (youssef.daali@hcuge.ch)
Sylvie Chevret (sylvie.chevret@univ-paris-diderot.fr)
Isabelle Nieto (isabel.nieto@aphp.fr)
Fanny Molière (f-moliere@chu-montpellier.fr)
Philippe Courtet (philippe.courtet@univ-montp1.fr)
Florence Galtier (f-galtier@chu-montpellier.fr)
Raphaëlle Richieri (raphaellemarie.richieri@ap-hm.fr)
Sophie Morange (sophie.morange@ap-hm.fr)
Pierre-Michel Llorca (pmllorca@chu-clermontferrand.fr)
Wissam El-Hage (wissam.elhage@univ-tours.fr)
Thomas Desmidt (thomas.desmidt@univ-tours.fr)
Frederic Haesebaert (frederic.haesebaert@ch-le-vinatier.fr)
Philippe Vignaud (philippe.vignaud@ch-le-vinatier.fr)
Jerome Holtzmann (jholtzmann@chu-grenoble.fr)
Jean-Luc Cracowski (jlcracowski@chu-grenoble.fr)
Antoine Yrondi (yrondi.a@chu-toulouse.fr)
Marion Leboyer (marion.leboyer@inserm.fr)
Fabienne Calvas (fabienne.calvas@inserm.fr)
Liova Yon (liova.yon@aphp.fr)
Author’s response to reviews:

Paris, 20th June 2017

Dear Professor Ragen,

Thank you very much for the attention you have paid to our manuscript entitled "Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study. MetAbolism vaRiability of VEUnafoxine (MARVEL study)". Please find below the specific answers to each comment.

Dr Celia Lloret-Linares, MD, PhD
Hôpital Lariboisière– Département de Médecine Interne
2 rue Ambroise Paré-75010 Paris – France
Tel: 33-1-49 95 81 27 ; Fax: 33-1-49 95 84 46

Email: celialloret@yahoo.fr, celia.lloret-linares@aphp.fr

The manuscript does not contain any individual persons data

Our data will not be shared before having performed all the statistical analysis for the publication.

**Declarations**

- **Ethics approval:** This document has been joined, it includes all the approval of the two governmental departments. The French Ethical committee and the Ministry for Public Health ANSM ((French National Agency for Medicines and Health Products Safety) authorised the study.

- In the manuscript, in the ethics part, is written: « Ethical approval was obtained by an Independent Ethics Committee (CPP Ile de France I, Paris) and by the Agence Française de Sécurité Sanitaire des Produits de Santé (ANSM, French Health Products Safety Agency). The study was registered at the ClinicalTrials.gov website (NCT02590185).”

- **Consent to participate:** consent to participate is a document written in French as this study only includes French people. The ethical committee has validated the document. The document is joined.

- **Consent to publish:** I am not sure to understand. The consent to participate includes that the results will be published and the patients give their agreement.

- **Availability of data and materials:** the data will not be communicated until the end of the study where statistical analysis will take place.

- **Competing interests:** none (as written before the references)
- Funding: This study was supported by a grant from the French Ministry of Health (MARVEL, 2015, P140935)

- Acknowledgements: none (as written before the references)

- Authors' Information and Authors' Contributions: the title page linked included the addresses of each author. I have included their role in the study.